Skip to content
The Nexus
BUSINESSJul 16 · 10:48 UTCCNBC TOP

Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction

Eli Lilly is acquiring AtaiBeckley for $2.8 billion to gain access to experimental psychedelic drugs based on DMT and MDMA.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned
Eli LillyorganizationAtaiBeckleyorganizationDMTtopicMDMAtopic
Spot something wrong with this article?Report a problem →
Forward this
Related Signal

Adjacent reporting